Rigorous review process leads to reaccreditation for high quality care for patients needing cellular treatment
(WILMINGTON, Del. – February 2, 2023)
The Bone Marrow and Stem Cell Transplant Program at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute has earned three-year reaccreditation by the Foundation for the Accreditation of Cellular Therapy (FACT), which sets worldwide standards for care in cellular therapy. The Graham Cancer Center’s program is the only one in the state and has received FACT accreditation since 2000.
A FACT accreditation indicates the Graham Cancer Center has met the most rigorous standards in every aspect of stem cell therapy.
The FACT accreditation is for adult allogeneic (from a related or unrelated donor) and autologous (self-donated) hematopoietic progenitor cellular therapy, immune effector cellular therapy, marrow cellular therapy product collection and peripheral blood cellular therapy product collection.
“Our continuous FACT accreditation since 2000 reinforces the high standards of excellence that our program delivers to patients with leukemia, lymphoma or other life-threatening diseases or blood disorders who need the most effective care to improve or prolong their lives,” said Nicholas Petrelli, M.D., Bank of America Endowed Medical Director of the Helen F. Graham Cancer Center & Research Institute at ChristianaCare. “With FACT accreditation our patients and community can rest assured that our Bone Marrow and Stem Cell Transplant Program is among the very best cellular therapy treatment programs in the greater Philadelphia region.”
FACT, which is based at the University of Nebraska Medical Center, is an internationally recognized accrediting body for hospitals and medical institutions offering stem cell transplant. Accreditation standards are set by leading experts based on the latest knowledge of the field of cellular therapy transplantation.
Bone marrow and stem cell transplants can be lifesaving for people with blood cancers, solid tumors and some non-cancerous blood disorders. The Graham Cancer Center’s Bone Marrow Transplant Unit at Christiana Hospital is one of the only such programs in our region, serving patients in Delaware and surrounding communities in Maryland, Pennsylvania and New Jersey. The program offers the most advanced and sophisticated techniques in bone marrow and stem cell therapy. Its hematologists/oncologists are part of a multidisciplinary team of experts ready to assist patients in their care.
Need an expert source?
Our Experts, ChristianaCare's expert database, can help you find the right source for your next news story.
Request an interview ➜
About the Helen F. Graham Cancer Center & Research Institute
The Helen F. Graham Cancer Center & Research Institute, a National Cancer Institute Community Oncology Research Program, is part of the ChristianaCare, one of the country’s most dynamic health systems, centered on improving health outcomes, making high-quality care more accessible and lowering health care costs. With more than 245,000 patient visits last year, the Graham Cancer Center is recognized as a national model for multidisciplinary cancer care and a top enroller in U.S. clinical research trials. In conjunction with the Gene Editing Institute, the Center for Translational Cancer Research, the Tissue Procurement Center, statewide High-Risk Family Cancer Registry and collaborations with world-renowned scientists at facilities such as The Wistar Institute in Philadelphia scientists are opening new avenues to more quickly translate cancer science into cancer medicine. For more information, visit christianacare.org/cancer.